Mer­ck gets a patent win for mus­cle re­lax­ant re­ver­sal drug

Mer­ck won a patent law­suit that al­lows it to keep mar­ket­ing a block­buster surgery drug un­til ear­ly 2026.

The phar­ma com­pa­ny said Tues­day that the US Dis­trict Court for the Dis­trict of New Jer­sey ruled in its fa­vor, say­ing Mer­ck had cor­rect­ly cal­cu­lat­ed the pe­ri­od of a Patent Term Ex­ten­sion, a reg­u­la­to­ry tool that can be used to re­store some patent time lost dur­ing reg­u­la­to­ry re­view of a new drug.

“We look for­ward to con­tin­u­ing to pro­vide Brid­ion to pa­tients who need it,” a Mer­ck spokesper­son said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.